BioSpace News Archive

Altamira Therapeutics today announced the publication of a peer-reviewed article in the scientific journal International Journal of Oral Science.

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows.

Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for additional claims that cover its oral testosterone replacement product, JATENZO (testosterone undecanoate).

Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022.

Iroquois Capital Management, LLC announced that it has filed preliminary consent materials with the SEC regarding its solicitation of written consents from stockholders in lieu of a stockholder meeting to reconstitute a majority of the PharmaCyte Board of Directors with its slate of highly qualified nominees.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS).

TetraScience, the Scientific Data Cloud company, announced today that ACD/Labs, a leading provider of scientific software for R&D, has joined the Tetra Partner Network to help pharma and biopharma customers achieve greater scientific insights and outcomes.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today reported positive preliminary pilot study data from its ongoing Expanded Access Program (“EAP or “AMP-511”) evaluating its investigational drug, Ampligen, as a therapeutic for “long COVID”.

VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced a new collaboration with Gestalt Diagnostics of Spokane, WA, to further advance digitization in pathology labs.